Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

por Konteatis, Zenon, Artin, Erin, Nicolay, Brandon, Straley, Kimberly, Padyana, Anil K., Jin, Lei, Chen, Yue, Narayaraswamy, Rohini, Tong, Shuilong, Wang, Feng, Zhou, Ding, Cui, Dawei, Cai, Zhenwei, Luo, Zhiyong, Fang, Cheng, Tang, Huachun, Lv, Xiaobing, Nagaraja, Raj, Yang, Hua, Su, Shin-San M., Sui, Zhihua, Dang, Lenny, Yen, Katharine, Popovici-Muller, Janeta, Codega, Paolo, Campos, Carl, Mellinghoff, Ingo K., Biller, Scott A.
Publicado 2020

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

por Popovici-Muller, Janeta, Lemieux, René M., Artin, Erin, Saunders, Jeffrey O., Salituro, Francesco G., Travins, Jeremy, Cianchetta, Giovanni, Cai, Zhenwei, Zhou, Ding, Cui, Dawei, Chen, Ping, Straley, Kimberly, Tobin, Erica, Wang, Fang, David, Muriel D., Penard-Lacronique, Virginie, Quivoron, Cyril, Saada, Véronique, de Botton, Stéphane, Gross, Stefan, Dang, Lenny, Yang, Hua, Utley, Luke, Chen, Yue, Kim, Hyeryun, Jin, Shengfang, Gu, Zhiwei, Yao, Gui, Luo, Zhiyong, Lv, Xiaobing, Fang, Cheng, Yan, Liping, Olaharski, Andrew, Silverman, Lee, Biller, Scott, Su, Shin-San M., Yen, Katharine
Publicado 2018